Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
Authors:
- Brian J. P. HuntlyBHBrian J. P. Huntly
- Alistair G. ReidARAlistair G. Reid
- Anthony J. BenchABAnthony J. Bench
- Lynda J. CampbellLCLynda J. Campbell
- Nick TelfordNTNick Telford
- Patricia ShepherdPSPatricia Shepherd
- Jeff SzerJeff Szer
- H. Miles PrinceH. Miles Prince
- Paul TurnerPTPaul Turner
- Colin GraceCGColin Grace
- Elizabeth P. NachevaENElizabeth P. Nacheva
- Anthony R. GreenAGAnthony R. Green
- 15 September 2001
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 98 (6) , 1732-1738
Abstract
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Large deletions on the derivative chromosome 9 have recently been reported, but it was unclear whether deletions arose during disease progression or at the time of the Ph translocation. Fluorescence in situ hybridization (FISH) analysis was used to assess the deletion status of 253 patients with CML. The strength of deletion status as a prognostic indicator was then compared to the Sokal and Hasford scoring systems. The frequency of deletions was similar at diagnosis and after disease progression but was significantly increased in patients with variant Ph translocations. In patients with a deletion, all Ph+metaphases carried the deletion. The median survival of patients with and without deletions was 38 months and 88 months, respectively ( P = .0001). By contrast the survival difference between Sokal or Hasford high-risk and non–high-risk patients was of only borderline significance ( P = .057 and P = .034). The results indicate that deletions occur at the time of the Ph translocation. An apparently simple reciprocal translocation may therefore result in considerable genetic heterogeneity ab initio , a concept that is likely to apply to other malignancies associated with translocations. Deletion status is also a powerful and independent prognostic factor for patients with CML. The prognostic significance of deletion status should now be studied prospectively and, if confirmed, should be incorporated into management decisions and the analysis of clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase βOncogene, 1999
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysisCancer Genetics and Cytogenetics, 1994
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Variant Philadelphia translocations in chronic myeloid leukemiaCytogenetic and Genome Research, 1987
- The incidence, type, and subsequent evolution of 14 variant Ph1 translocations in 180 South African patients with Ph1-positive chronic myeloid leukemiaCancer Genetics and Cytogenetics, 1984
- Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22Cell, 1984
- Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1983